Литература
- Davis E. C., Callender V. D. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010, № 3(7): 20–31.
- Passeron T. Melasma pathogenesis and influencing factors — an overview of the latest research. J Eur Acad Dermatol Venereol. 2013, № 27(Suppl 1): 5–6.
- Passeron T., Desai S. R., Abdallah M., et al. Global consensus on the management of melanin hyperpigmentation disorders. J Eur Acad Dermatol Venereol. 2026, № 40: 760–772.
- Frey C., Grimes P., Callender V., et al. Thiamidol: A Breakthrough Innovation in the Treatment of Hyperpigmentation. J Drugs Dermatol. 2025, № 24(6): 608.
- Mann T., Gerwat W., Batzer J., et al. Inhibition of human tyrosinase requires molecular motifs distinctively different from mushroom tyrosinase. J Invest Dermatol. 2018, № 138(7): 1601–1608.
- Vachiramon V., Sakpuwadol N., Yongpisarn T., et al. Efficacy of isobutylamido thiazolyl resorcinol for prevention of laser-induced post-inflammatory hyperpigmentation: a randomized, controlled trial. J Cosmet Dermatol. 2024, № 23(7): 2450–2457.
- Vachiramon V., Leerunyakul K., Kositkuljorn C., Chayavichitsilp P. Combined isobutylamido thiazolyl resorcinol and low-fluence Q-switched Nd:YAG laser for the treatment of facial hyperpigmentation: a randomized, split-face study. J Cosmet Dermatol. 2021, № 20(6): 1724–1731.
- Moolla S., Miller-Monthrope Y. Dermatology: how to manage facial hyperpigmentation in skin of colour. Drugs Context. 2022, № 11: 2021-11-2.